POK: Computer-assisted diagnostic software for lesions suspicious for cancer
What it covers
Prescription image processing software that helps users characterize lesions already identified on images such as MR, mammography, radiography or CT as suspicious for cancer. Diagnostic and patient management decisions are made by the clinical user.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K261679 | BlineSlide | Deep Breathe, Inc. | Oct 23, 2026 | Traditional |
| K253884 | Koios DS (3.8) | Koios Medical, Inc. | Jul 2, 2026 | Traditional |
| K261519 | Sonio Suspect | Sonio | Jun 4, 2026 | Special |
| K254161 | Automated Aortic Stenosis Software (AutoAS) | GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC | Mar 27, 2026 | Traditional |
| K251769 | RevealAI-Lung | Precision Medical Ventures, Inc. Dba Revealdx | Jan 30, 2026 | Traditional |
| K252294 | Fetal EchoScan (v1.2) | Brightheart | Dec 8, 2025 | Traditional |
| K250221 | StrokeSENS ASPECTS Software Application | Circle Cardiovascular Imaging, Inc. | Jul 1, 2025 | Traditional |
| K251071 | Fetal EchoScan (v1.1) | Brightheart | May 2, 2025 | Special |
| K243614 | Sonio Suspect | Sonio | Feb 21, 2025 | Traditional |
| K243294 | Brainomix 360 e-ASPECTS | Brainomix Limited | Feb 14, 2025 | Traditional |
Clearances by year
23 POK 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 4 | 153 |
| 2025 | 5 | 119 |
| 2024 | 6 | 161 |
| 2023 | 1 | 268 |
| 2022 | 1 | 169 |
| 2021 | 2 | 162 |
| 2020 | 2 | 143 |
| 2019 | 1 | 128 |
| 2017 | 1 | 103 |
Who submits
15 applicants cleared a POK device since 2011. 43% of the clearances went to applicants in United States, then France (26%), United Kingdom (17%) and Australia (4%). By type: Traditional 87%, Special 9% and Direct 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Koios Medical, Inc. | 4 |
| Brightheart | 3 |
| Brainomix Limited | 2 |
| Ischemaview, Inc. | 2 |
| Sonio | 2 |
| Aisap | 1 |
| Avenda Health, Inc. | 1 |
| Avicenna.Ai | 1 |
What the special controls require
From the special controls in 21 CFR 892.2060(b)(1), which also set labeling requirements. Read the source.
- A detailed description of the image analysis algorithms, their inputs and outputs, and their limitations
- Pre-specified performance testing protocols and datasets that assess whether the device improves reader performance
- Results showing improved reader performance in the intended use population, with diagnostic accuracy measures and enough cases per important cohort
- Standalone performance testing protocols and results
- Software documentation, including hazard analysis, traceability, verification and validation, and cybersecurity
Standards
21 CFR 892.2060 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent POK clearances declared.
POK is one of the product codes most common on FDA’s list of AI-enabled devices. See how FDA regulates AI-enabled medical devices.
Ask about POK
Questions about POK
What is FDA product code POK?
Product code POK covers computer-assisted diagnostic software for lesions suspicious for cancer, Class II devices regulated under 21 CFR 892.2060 and reviewed by FDA's Radiology panel. FDA's 510(k) database lists 24 clearances under POK.
How many 510(k) clearances are there under POK?
FDA’s 510(k) database listed 24 clearances under POK as of Nov 16, 2026, 23 of them decided since 2011; the most recent decision was Oct 23, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a POK 510(k)?
For the 11 POK clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 116 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most POK clearances?
Since 2011: Koios Medical, Inc. (4), Brightheart (3), Brainomix Limited (2), Ischemaview, Inc. (2) and Sonio (2). 15 applicants have cleared a POK device in that time.
What testing do POK submissions include?
From the special controls in 21 CFR 892.2060(b)(1), which also set labeling requirements. In short: a detailed description of the image analysis algorithms, their inputs and outputs, and their limitations; pre-specified performance testing protocols and datasets that assess whether the device improves reader performance; results showing improved reader performance in the intended use population, with diagnostic accuracy measures and enough cases per important cohort; standalone performance testing protocols and results; software documentation, including hazard analysis, traceability, verification and validation, and cybersecurity.